vs
Side-by-side financial comparison of Alexandria Real Estate Equities (ARE) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Alexandria Real Estate Equities is the larger business by last-quarter revenue ($671.0M vs $346.4M, roughly 1.9× HAEMONETICS CORP). Alexandria Real Estate Equities runs the higher net margin — 59.4% vs 28.1%, a 31.3% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (4.8% vs -11.5%). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (1.5% CAGR vs -6.4%).
Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® urban office real estate investment trust (REIT), is the first, longest-tenured, and pioneering owner, operator, and developer uniquely focused on collaborative life science, technology, and agtech campuses in AAA innovation cluster locations, with a total market capitalization of $31.9 billion as of December 31, 2020, and an asset base in North America of 49.7 million square feet (SF). The asset base in North America includes 31.9...
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
ARE vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $671.0M | $346.4M |
| Net Profit | $398.4M | $97.3M |
| Gross Margin | — | 57.2% |
| Operating Margin | — | 36.1% |
| Net Margin | 59.4% | 28.1% |
| Revenue YoY | -11.5% | 4.8% |
| Net Profit YoY | 740.6% | — |
| EPS (diluted) | $2.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $671.0M | $346.4M | ||
| Q4 25 | $754.4M | $339.0M | ||
| Q3 25 | $751.9M | $327.3M | ||
| Q2 25 | $762.0M | $321.4M | ||
| Q1 25 | $758.2M | $330.6M | ||
| Q4 24 | $788.9M | $348.5M | ||
| Q3 24 | $791.6M | $345.5M | ||
| Q2 24 | $766.7M | $336.2M |
| Q1 26 | $398.4M | $97.3M | ||
| Q4 25 | $-1.1B | $44.7M | ||
| Q3 25 | $-232.8M | $38.7M | ||
| Q2 25 | $-107.0M | $34.0M | ||
| Q1 25 | $-8.9M | $58.0M | ||
| Q4 24 | $-62.2M | $37.5M | ||
| Q3 24 | $167.9M | $33.8M | ||
| Q2 24 | $46.7M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | — | 19.9% | ||
| Q3 25 | — | 17.9% | ||
| Q2 25 | — | 16.8% | ||
| Q1 25 | — | 21.6% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 15.0% | ||
| Q2 24 | — | 11.8% |
| Q1 26 | 59.4% | 28.1% | ||
| Q4 25 | -143.3% | 13.2% | ||
| Q3 25 | -31.0% | 11.8% | ||
| Q2 25 | -14.0% | 10.6% | ||
| Q1 25 | -1.2% | 17.5% | ||
| Q4 24 | -7.9% | 10.8% | ||
| Q3 24 | 21.2% | 9.8% | ||
| Q2 24 | 6.1% | 11.4% |
| Q1 26 | $2.10 | — | ||
| Q4 25 | $-6.35 | $0.95 | ||
| Q3 25 | $-1.38 | $0.81 | ||
| Q2 25 | $-0.64 | $0.70 | ||
| Q1 25 | $-0.07 | $1.17 | ||
| Q4 24 | $-0.38 | $0.74 | ||
| Q3 24 | $0.96 | $0.66 | ||
| Q2 24 | $0.25 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $418.7M | $245.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $19.4B | $796.3M |
| Total Assets | $34.2B | $2.4B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $418.7M | $245.4M | ||
| Q4 25 | $549.1M | $363.4M | ||
| Q3 25 | $579.5M | $296.4M | ||
| Q2 25 | $520.5M | $292.9M | ||
| Q1 25 | $476.4M | $306.8M | ||
| Q4 24 | $552.1M | $320.8M | ||
| Q3 24 | $562.6M | $299.3M | ||
| Q2 24 | $561.0M | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $12.4B | $1.2B | ||
| Q3 25 | $13.6B | $1.2B | ||
| Q2 25 | $13.3B | $1.2B | ||
| Q1 25 | $13.1B | $1.2B | ||
| Q4 24 | $12.2B | — | ||
| Q3 24 | $12.7B | — | ||
| Q2 24 | $12.4B | — |
| Q1 26 | $19.4B | $796.3M | ||
| Q4 25 | $15.5B | $911.5M | ||
| Q3 25 | $16.6B | $849.2M | ||
| Q2 25 | $17.2B | $882.3M | ||
| Q1 25 | $17.5B | $820.8M | ||
| Q4 24 | $17.9B | $906.9M | ||
| Q3 24 | $18.2B | $878.9M | ||
| Q2 24 | $18.3B | $905.4M |
| Q1 26 | $34.2B | $2.4B | ||
| Q4 25 | $34.1B | $2.5B | ||
| Q3 25 | $37.4B | $2.4B | ||
| Q2 25 | $37.6B | $2.5B | ||
| Q1 25 | $37.6B | $2.5B | ||
| Q4 24 | $37.5B | $2.5B | ||
| Q3 24 | $38.5B | $2.5B | ||
| Q2 24 | $37.8B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | 0.80× | 1.34× | ||
| Q3 25 | 0.82× | 1.44× | ||
| Q2 25 | 0.77× | 1.39× | ||
| Q1 25 | 0.75× | 1.49× | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.68× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $196.6M | $293.2M |
| Free Cash FlowOCF − Capex | — | $209.9M |
| FCF MarginFCF / Revenue | — | 60.6% |
| Capex IntensityCapex / Revenue | 76.0% | 9.5% |
| Cash ConversionOCF / Net Profit | 0.49× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | — | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $196.6M | $293.2M | ||
| Q4 25 | $312.4M | $93.6M | ||
| Q3 25 | $433.5M | $111.3M | ||
| Q2 25 | $460.2M | $17.4M | ||
| Q1 25 | $207.9M | $116.6M | ||
| Q4 24 | $274.2M | $43.8M | ||
| Q3 24 | $477.4M | $48.8M | ||
| Q2 24 | $411.8M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | — | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | -9.8% |
| Q1 26 | 76.0% | 9.5% | ||
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 1.7% |
| Q1 26 | 0.49× | 3.01× | ||
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | 2.84× | 1.44× | ||
| Q2 24 | 8.82× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARE
| Same properties | $431.4M | 64% |
| Tenant recoveries | $178.2M | 27% |
| Non-same properties | $43.3M | 6% |
| Other | $18.0M | 3% |
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
